Several other brokerages have also commented on GLPG. ValuEngine raised shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 4th. HC Wainwright boosted their price target on shares of GALAPAGOS NV/S to $150.00 and gave the company a “positive” rating in a research report on Friday, March 29th. Zacks Investment Research lowered shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Svb Leerink began coverage on shares of GALAPAGOS NV/S in a research report on Friday, February 22nd. They issued an “outperform” rating on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research note on Friday, February 22nd. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $127.27.
GALAPAGOS NV/S stock traded up $1.33 during midday trading on Thursday, hitting $116.78. 163,070 shares of the stock were exchanged, compared to its average volume of 109,039. The stock has a market cap of $5.92 billion, a PE ratio of -176.94 and a beta of 1.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.31. GALAPAGOS NV/S has a 52-week low of $85.00 and a 52-week high of $125.48.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
See Also: Total Return
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.